secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2023-06-01T23:59:59+00:00
Accession:  0001193125-23-158979
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst reaffirms FY2023 revenue $375M-$385M; non-GAAP net income $195M-$205M
------------------------------------------------------------------------------

- Reaffirms full-year 2023 total revenue guidance of $375M to $385M, 75-80% YoY increase.
- FIRDAPSE net product revenue guided $245M-$255M, up 17% vs. 2022.
- FYCOMPA net product revenue forecast at ~$130M for 11 months after Jan. 24 acquisition.
- Non-GAAP net income forecast of $195M to $205M for full-year 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523158979/0001193125-23-158979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523158979/d463989d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-158979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer